Kerala HC: Persons With Down Syndrome Get Protection and Guardianship under National Trust Act, 1999  ||  J&K&L HC: Contractual Staff Cannot Claim Payment Beyond Contract Period Without Proving Work  ||  J&K&L HC: Revisional Powers U/S 15 Must be Exercised in Reasonable Time, Not After 20-Year Delay  ||  MP High Court: Revoking Building Permission Without Fraud Proof Violates Right to Property  ||  Madras HC: Centre’s Consent For Remission is Needed only When Sentence under Central Act is Ongoing  ||  Delhi HC: Private School Employees Entitled to Child Care Leave Equivalent to Government Employees  ||  Supreme Court Has Released Draft Regulations on AI Use in the Judiciary and Invited Public Feedback  ||  Supreme Court: MMDR Act Royalty Hikes Prevail over Contractual Terms  ||  Delhi HC: Daughter-In-Law Has No Independent Right in Mother-In-Law’s Self-Acquired House  ||  SC: Prolonged Separation Can Constitute Cruelty and Desertion    

CCI approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.- (Press Information Bureau) (16 Mar 2022)

MANU/PIBU/0878/2022

MRTP/ Competition Laws

The Competition Commission of India (CCI) approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.

The proposed combination pertains to the proposed acquisition of minority stake in Micro Life Sciences Private Limited (Micro Life/ Target) by South Elm Investments B.V. (SEI/ Acquirer).

SEI is an investment holding company incorporated under the laws of Netherlands. The shareholders of SEI are certain private equity funds managed by Warburg Pincus LLC.

Target is a company incorporated in India, which is primarily engaged in the following business activities in India along with subsidiaries: manufacture and sale of (a) medical devices in various categories such as stents, Percutaneous Transluminal Coronary Angioplasty catheters, heart valves, orthopedic implants, and endo-surgery products (such as sutures, staplers, meshes and intrauterine devices); (b) in-vitro diagnostics analyzers and reagents; and (c) over the counter (OTC) products like products COVID self-test kits and pregnancy test kits, in India. The Target (through its subsidiaries) is engaged in the B2C sale of certain specialized medical devices (such as surgical robots and ultrasonic energy devices) to hospitals and has research and development (R&D) facilities for in-vitro diagnostic, orthopedic, endo-surgery and cardiovascular solutions.

Tags : ACQUISITION   APPROVAL   MINORITY STAKE  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved